<DOC>
	<DOCNO>NCT00486343</DOCNO>
	<brief_summary>Asthma chronic inflammatory disorder airway variety inflammatory process contribute pathogenesis . The inflammation lead state increase airway responsiveness reversible airway obstruction cause recurrent symptom asthma . Despite variety treatment available asthma , none curative , disease continue place burden society term morbidity , reduce quality life ( QOL ) , ever increase healthcare cost . The prevalence asthma continue increase current data suggest since 1980 , adult asthma case increase 75 % child 5 year age prevalence increase 160 % .1 Additionally , study suggest disease severity underestimated patient may classify moderate severe persistent disease.2 Inhaled corticosteroid ( ICS ) cornerstone anti-inflammatory treatment decade show improve lung function , decrease symptom , reduce asthma exacerbations.3 However , many patient still inadequately control despite treatment accord current asthma management guideline significant unmet medical need . Such patient high risk serious exacerbation asthma-related mortality.4 Combining long-acting Î²2-agonists ( LABAs ) low dose ICS show improve asthma control use high dos ICS alone . However , LABAs act mainly bottom inflammatory cascade concern may mask underlie inflammation.5 Recently , leukotriene receptor antagonists add ICS second-line therapy management asthma . Zileuton extensively study inflammatory disease asthma , leukotrienes mediate inflammation . The aim study assess effect zileuton controlled-release ( CR ; 1200 mg 2-times daily [ BID ] ) pulmonary function , asthma control , symptomatic response adult patient asthma poorly control moderate dose ICS .</brief_summary>
	<brief_title>Zileuton CR v Placebo Poorly Controlled Asthma Patients Moderate Dose ICS</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>1 . Male female 1270 year age ( inclusive ) . 2 . Diagnosis asthma least 6 month . 3 . Morning FEV1 4080 % normal . 4 . Demonstrated reversible airflow restriction . 5 . Nonsmokers . 6 . On moderate dos ICS inadequate asthma control . 7 . Signed ICF 1 . Diagnosis COPD . 2 . Uncontrolled systemic illness . 3 . Hypersensitivity component ZYFLO CR 4 . Any patient unscheduled visit ER hospital asthma exacerbation within past 3 month . 5 . History hepatitis active liver disease . 6 . ALT great 3xULN . 7 . History HIV infection 8 . Recent history drug alcohol abuse . 9 . Oral corticosteroid within one month , cromolyn sodium nedocromil within 14 day , theophylline , LABA , ZYFLO , leukotriene modifier , warfarin propranolol , inhaled anticholinergic , combination LABA/ICS . 10 . Omalizumab within 3 month . 11 . Pregnant female . 12 . Participation 30 day investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>ICS</keyword>
	<keyword>5-LO Inhibition</keyword>
	<keyword>Leukotrienes</keyword>
	<keyword>Asthma control</keyword>
	<keyword>Asthma exacerbation</keyword>
</DOC>